The healthcare sector underperformed broader equities in 2025, but that shouldn't deter investors. Many companies in the ...

Axsome Therapeutics (AXSM) has quickly moved onto investors' radar after the FDA accepted a priority review for AXS-05 in Alzheimer’s agitation and signaled support for an NDA filing for narcolepsy ...

H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $185 and keeps a Buy rating on the shares after the ...

A CNS-focused biopharmaceutical company headquartered in New York City. The company commercializes products in the United ...

Needham analyst Ami Fadia raised the firm’s price target on Axsome Therapeutics (AXSM) to $225 from $169 and keeps a Buy rating on the shares. The ...

In a report released today, Ashwani Verma from UBS maintained a Buy rating on Axsome Therapeutics, with a price target of $248.00. According to TipRanks, Verma is a 4-star analyst with an average ...

The US Food and Drug Administration (FDA) has accepted for filing Axsome Therapeutics’ supplemental New Drug Application (NDA ...

US FDA accepts Axsome Therapeutics’ supplemental New Drug Application for AXS-05 to treat Alzheimer’s disease agitation: New York Saturday, January 3, 2026, 12:00 Hrs [IST] Ax ...

Detailed price information for Genedx Holdings Corp (WGS-Q) from The Globe and Mail including charting and trades.

Nearly half of all patients with hemorrhagic stroke also experience headache across its acute and chronic phases that could ...

Oppenheimer Research released a list of its best ideas for small-caps and mid-caps in the new year.

Flanigans Enterprises INC (EXCHANGE:BDL) CEO and President James Flanigan II recently increased his stake in the company through a series of transactions. According to SEC filings, Flanigan acquired a ...